To evaluate the anti-leukemic efficacy in vivo, six-week-old female NSG or NRG mice were injected intravenously with FLT3-ITD expressing acute myeloid leukemia cells (MV4–11), expressing luciferase. This evidence concerns the gene FLT3 and acute myeloid leukemia.